{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T03:41:36Z","timestamp":1781494896835,"version":"3.54.1"},"reference-count":10,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","eu-focus.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Focus"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.euf.2025.11.013","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:05:42Z","timestamp":1764882342000},"page":"28-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Prostate Cancer: Current Status of Novel Molecular Imaging and Future Prospects"],"prefix":"10.1016","volume":"12","author":[{"suffix":"3rd","given":"Donald C.","family":"Wunsch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0853-6494","authenticated-orcid":false,"given":"Baris","family":"Turkbey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euf.2025.11.013_b0005","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1007\/s11912-025-01682-2","article-title":"The evolving role of PSMA-PET\/CT in prostate cancer management: an umbrella review of diagnostic restaging, therapeutic redirection, and survival impact","volume":"27","author":"Wang","year":"2025","journal-title":"Curr Oncol Rep"},{"key":"10.1016\/j.euf.2025.11.013_b0010","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/s11934-025-01268-2","article-title":"The role of PSMA PET imaging in prostate cancer: current applications and future directions","volume":"26","author":"Islam","year":"2025","journal-title":"Curr Urol Rep"},{"key":"10.1016\/j.euf.2025.11.013_b0015","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","article-title":"Prospective intra-individual blinded comparison of [18F]PSMA-1007 and 68Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer","volume":"49","author":"Pattison","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6 Suppl","key":"10.1016\/j.euf.2025.11.013_b0020","doi-asserted-by":"crossref","first-page":"009","DOI":"10.1200\/JCO.2022.40.6_suppl.009","article-title":"Detection rate of 18F-rhPSMA-7.3 PET in patients with suspected prostate cancer recurrence: results from a phase 3, prospective, multicenter study (SPOTLIGHT)","volume":"40","author":"Schuster","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euf.2025.11.013_b0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2967\/jnumed.117.198119","article-title":"Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT","volume":"59","author":"Eiber","year":"2018","journal-title":"J Nucl Med"},{"key":"10.1016\/j.euf.2025.11.013_b0030","article-title":"Comparison of Prostate-specific Membrane Antigen Reporting and Data System version 1.0 versus 2.0 for prostate cancer assessment. Radiol Imaging","volume":"7","author":"Almalki","year":"2025","journal-title":"Cancer"},{"key":"10.1016\/j.euf.2025.11.013_b0035","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.eururo.2020.11.013","article-title":"Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177-PSMA","volume":"79","author":"Feuerecker","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.euf.2025.11.013_b0040","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given 177Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Hofman","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euf.2025.11.013_b0045","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13550-025-01265-z","article-title":"A prospective, multi-centre trial of PSMA-PET compared to FDG-PET for staging of newly diagnosed high risk prostate cancer","volume":"15","author":"Roberts","year":"2025","journal-title":"EJNMMI Res"},{"key":"10.1016\/j.euf.2025.11.013_b0050","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1097\/RLU.0000000000005064","article-title":"Contribution of 68Ga-DOTA-FAPI-04 PET\/CT to prostate cancer imaging: complementary role in PSMA-negative cases","volume":"49","author":"Erg\u00fcl","year":"2024","journal-title":"Clin Nucl Med"}],"container-title":["European Urology Focus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003451?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405456925003451?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T18:58:23Z","timestamp":1770145103000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405456925003451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2405456925003451"],"URL":"https:\/\/doi.org\/10.1016\/j.euf.2025.11.013","relation":{},"ISSN":["2405-4569"],"issn-type":[{"value":"2405-4569","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prostate Cancer: Current Status of Novel Molecular Imaging and Future Prospects","name":"articletitle","label":"Article Title"},{"value":"European Urology Focus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euf.2025.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V. on behalf of European Association of Urology.","name":"copyright","label":"Copyright"}]}}